Odyssean LLC Buys Shares of 26,232 Twist Bioscience Corporation $TWST

Odyssean LLC bought a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 26,232 shares of the company’s stock, valued at approximately $2,699,000.

Other institutional investors also recently modified their holdings of the company. Allworth Financial LP acquired a new stake in shares of Twist Bioscience during the 2nd quarter valued at $62,000. Trifecta Capital Advisors LLC bought a new stake in Twist Bioscience during the 2nd quarter worth $63,000. Western Wealth Management LLC acquired a new position in Twist Bioscience in the 1st quarter worth about $31,000. Strs Ohio acquired a new position in Twist Bioscience in the 1st quarter worth about $33,000. Finally, GAMMA Investing LLC raised its position in Twist Bioscience by 24.4% in the second quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after purchasing an additional 185 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have recently commented on TWST. Canaccord Genuity Group lifted their price target on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Evercore downgraded Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective for the company. in a research note on Monday, July 6th. UBS Group set a $89.00 price objective on shares of Twist Bioscience in a report on Monday, June 15th. Barclays lifted their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Finally, Piper Sandler boosted their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $98.30.

Twist Bioscience Stock Up 7.5%

Shares of NASDAQ:TWST opened at $151.42 on Wednesday. The firm has a market cap of $9.50 billion, a P/E ratio of -68.21 and a beta of 2.14. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $154.96. The business has a fifty day simple moving average of $103.22 and a 200 day simple moving average of $71.89. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The company had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.33 EPS. Analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Adam Laponis sold 2,399 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $94.33, for a total value of $226,297.67. Following the sale, the chief financial officer directly owned 110,276 shares in the company, valued at $10,402,335.08. This represents a 2.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 14,205 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the transaction, the insider owned 105,141 shares of the company’s stock, valued at approximately $9,436,404.75. The trade was a 11.90% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 151,529 shares of company stock valued at $17,708,772 in the last ninety days. Insiders own 3.08% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.